5-Amino-1MQ

Overview

Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using S-adenosyl-methionine as the methyl donor. By inhibiting NNMT, the compound is studied for its reported effects on cellular nicotinamide and NAD+ salvage flux and on adipocyte energy expenditure, which places it in the metabolic and body-composition research literature alongside other metabolism-modulating compounds. It is a quaternary quinolinium small molecule, not a peptide. Vialdyne supplies Amino-1MQ as a research reagent released against an HPLC purity specification with mass-spec identity confirmation; the applicable batch COA lists the tests actually performed and, when included in the agreed scope, can cover HPLC purity, identification, water content, residual solvents, heavy metals, and microbial limits against a small-molecule reagent specification. Because salt form and exact identity vary across the market under the 'Amino-1MQ' label, lot identity is documented on the COA, confirm the intended form at order placement.

Applications & buyer fit

Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

(small-molecule research compound · lot identity confirmed on COA)

Appearance

White to off-white powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 50 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 1.2 hours

MOQ

On request

Lead time

10–18 days

Storage

Room temperature, protect from light

Certificate of Analysis

Representative COA previews for 5-Amino-1MQ; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

5-Amino-1MQ

VD260428-10AM016 · 99.59%

VerifiedRequest full COA →

5-Amino-1MQ

VD260428-50AM017 · 99.28%

VerifiedRequest full COA →

5-Amino-1MQ

VD260428-5AM015 · 99.25%

Independent analytical testing

Product- and strength-matched first-page previews are shown separately from Vialdyne's lot-specific Batch COAs. Reference the report number when requesting the complete, high-resolution file from sales.

Third-party testView report record →

5-Amino-1MQ

5 mg · HPLC / MS

5AM5-20260806S9397

Regulatory note

Research-use-only small-molecule reagent (NNMT inhibitor); not an approved drug in any jurisdiction and not for human or veterinary use.

Selected literature

1. Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018 Jan;147:141-152.
2. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262.
3. Babula JAJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024;26(11):5272-5282.
4. Awosemo O, Neelakantan H, Watowich SJ, Ma J, Wu L, Chow DS, Liang D. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021;204:114255.
5. Sun WD, Zhu XJ, Li JJ, Mei YZ, Li WS, Li JH. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Front Pharmacol. 2024;15:1410479.
6. Liu M, Chen H, Wei L, Hu Y, Yang G. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. Biomed Res Int. 2021;2021:9924314.

Frequently asked questions